Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Asset Writedowns and Impairment (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Asset Writedowns and Impairment for 11 consecutive years, with $25302.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Asset Writedowns and Impairment fell 94.47% year-over-year to $25302.0, compared with a TTM value of $12765.0 through Sep 2025, down 97.34%, and an annual FY2024 reading of $450738.0, up 5752.6% over the prior year.
  • Asset Writedowns and Impairment was $25302.0 for Q3 2025 at China Pharma Holdings, up from -$212670.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $457574.0 in Q3 2024 and bottomed at -$403601.0 in Q4 2021.
  • Average Asset Writedowns and Impairment over 5 years is $5331.5, with a median of -$4358.0 recorded in 2022.
  • Peak annual rise in Asset Writedowns and Impairment hit 10428.12% in 2025, while the deepest fall reached 2609.08% in 2025.
  • Year by year, Asset Writedowns and Impairment stood at -$403601.0 in 2021, then skyrocketed by 97.49% to -$10136.0 in 2022, then surged by 260.09% to $16227.0 in 2023, then plummeted by 181.63% to -$13246.0 in 2024, then soared by 291.02% to $25302.0 in 2025.
  • Business Quant data shows Asset Writedowns and Impairment for CPHI at $25302.0 in Q3 2025, -$212670.0 in Q2 2025, and $213379.0 in Q1 2025.